CAS: 127191-97-3; (S)-4-(2-(N-Methylisoquinoline-5-Sulfonamido)-3-Oxo-3-(4-Phenylpiperazin-1-yl)Propyl)Phenyl Isoquinoline-5-Sulfonate
- 英文名称(S)-4-(2-(N-Methylisoquinoline-5-Sulfonamido)-3-Oxo-3-(4-Phenylpiperazin-1-yl)Propyl)Phenyl Isoquinoline-5-Sulfonate
- 中文名称1-[N,O-二(5-异喹啉磺酰基)-N-甲基-L-型酪氨酸]-4-苯基哌嗪
- IUPAC名称(S)-4-(2-(N-methylisoquinoline-5-sulfonamido)-3-oxo-3-(4-phenylpiperazin-1-yl)propyl)phenyl isoquinoline-5-sulfonate
- 其它别名KN-62; 4-[(2S)-2-[(5-ISOQUINOLINYLSULFONYL)METHYLAMINO]-3-OXO-3-(4-PHENYL-1-PIPERAZINYL)PROPYL] PHENYL ISOQUINOLINESULFONIC ACID ESTER; 1-[N,O-BIS-(5-ISOQUINOLINESULFONYL)-N-METHYL-L-TYROSYL]-4-PHENYLPIPERAZINE; (S)-5-ISOQUINOLINESULFONIC ACID 4-(2-[(5-ISOQUINOLINYLSULFONYL)METHYLAMINO]- 3-OXO-3-[4-PHENYL-1-PIPERAZINYL]PROPYL)PHENYL ESTER; 1-(N,O-BIS-(5-ISOQUINOLINESULFONYL)-*N-M ETHYL-L-TYR; KN-62 ; KN-62, 99+%; 4-((2S)-2-((5-isoquinolinylsulfonyl)methylamino)-3-oxo-3-(4-phenyl-1-piperazinyl)propyl)phenylisoquinolinesulfonicacid
- CAS编号127191-97-3
- MFCD编号:MFCD00083180
- FDA UNII编号:63HM46XPOW
- 分子式:C38H35N5O6S2分子量:721.86
- 产品CID: 433162
- 产品分类生物化工 → 氨基酸及其衍生物 → 酪氨酸类衍生物
物理性质
- 熔点92-94 °C
- 沸点964.7±75.0 °C at 760 mmHg
- 闪点537.3±37.1 °C
- 密度1.4±0.1 g/cm3
- pKa:4.07±0.13(预测)
- PSA:146.84
- LogP:5.23
- 折射率1.686
- 蒸汽压0.0±0.3 mmHg at 25°C
- 溶解性45% (w/v) aq 2-羟丙基-β-环糊精:0.93 mg/mL
- 敏感性如果遵照规格使用和储存则不会分解，未有已知危险反应
- 外观形态白色固体
- 储存条件密封保存、在-20°C下保存
- 产品应用该化合物是一个P2X7R敌国(HP2X7 IC50 = 51 NM) 和 CA2+/CALMODULIN依赖蛋白质性顺质第二抑制剂. KN61 抑制体外和体外癌症细胞的侵入,KN62 在体外或体外导致大鼠反转性失忆. K N62 通过禁止依赖电压的卡(2+) 通道来缓解谷类动物的释放. KN62 对卡(2 +)----流入的影响似乎具体针对缓慢或不活跃的导体,因此将KN61作为一种潜在有用的工具.
MSDS等安全信息
合成工艺路线路线简述
📜1-[n,O-Bis(5-Isoquinolinesulfonyl)Tyrosyl]4-Phenylpiperazine,Sodium;Hydride,碘甲烷,水置于ice,乙酸乙酯,氯化钠,Magnesium Sulfate,Chloroform Methanol体系中,用 N,N-二甲基甲酰胺 用作溶剂,化学反应 1.5H,以to Obtain 1.8 G Of The Title Compound In A Yellow Amorphous Form的收率获得1-[n,O-二(5-异喹啉磺酰基)-N-甲基-L-型酪氨酸]-4-苯基哌嗪
参考文献:Compound Having Vessel Smooth Muscle Relaxation Activity
标题:Compound Having Vessel Smooth Muscle Relaxation Activity
摘要:一种新型喹啉磺酰氨衍生物,具有血管平滑肌松弛活性以及血小板凝聚抑制活性和对蛋白激酶a,肌球蛋白轻链激酶,蛋白激酶c和依赖钙调蛋白激酶ii的抑制活性,但对心脏功能影响较小;一种制备该衍生物的方法和含有该衍生物的制药组合物.
专利信息
专利号:US-6399107-B1
优先权日:1998-12-22
标 题:Use of inhibitors of gag synthesis for the treatment of corneal haze
发明人：KESSLER TIMOTHY L; NIXON JON C; DAVID KAREN C; GRAFF GUSTAV
权利人:ALCON LAB INC
摘要:This invention relates to the compositions and methods for the treatment of corneal haze. The compositions and methods are particularly directed to the use of GAG synthesis inhibitors in the treatment of corneal haze.
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Park JH, Lee GE, Lee SD, Hien TT, Kim S, Yang JW, Cho JH, Ko H, Lim SC, Kim YG, Kang KW, Kim YC. Discovery of novel 2,5-dioxoimidazolidine-based P2X(7) receptor antagonists as constrained analogues of KN62. J Med Chem. 2015 Mar 12;58(5):2114-34. doi: 10.1021/jm500324g. Epub 2015 Feb 23.
5: Marley PD, Thomson KA. The Ca++/calmodulin-dependent protein kinase II inhibitors KN62 and KN93, and their inactive analogues KN04 and KN92, inhibit nicotinic activation of tyrosine hydroxylase in bovine chromaffin cells. Biochem Biophys Res Commun. 1996 Apr 5;221(1):15-8.
合成参考文献
参考文献:10.1124/mol.119.116715
摘要:Bin Dayel A, Evans RJ, Schmid R. Mapping the Site of Action of Human P2X7 Receptor Antagonists AZ11645373, Brilliant Blue G, KN-62, Calmidazolium, and ZINC58368839 to the Intersubunit Allosteric Pocket. Molecular Pharmacology. 2019 Sep;96(3):355–63. doi: 10.1124/mol.119.116715.
参考文献:10.1023/b:neur.0000005599.10952.33
摘要:Wang W, Hou XY, Gao C, Liu Y, Zong YY, Zhang GY. Regulation of c-Jun N-terminal kinase activation in hydrogen peroxide induced neurotoxicity. J Neurocytol. 2003 Feb;32(2):143–51. doi: 10.1023/b:neur.0000005599.10952.33.
📝 需求与反馈
尽可能描述清楚需求与问题信息
